Navigation Links
Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
Date:8/19/2007

PETACH TIKVA, Israel, August 16 /PRNewswire-FirstCall/ -- Healthcare Technologies Ltd. (NASDAQ: HCTL), announced today that, it has scheduled an extraordinary general meeting of its shareholders to be held on September 30, 2007 at 11:00 a.m., at the offices of Yigal Arnon & Co., 1 Azrieli Center, Round Tower, 47th Floor, Tel Aviv, Israel.

At the meeting, shareholders will be asked to approve the previously announced Asset Purchase Agreement with NexGen Biofuels, Inc, Mac Bioventures Inc. and Gamida for Life B.V. and the transactions contemplated thereby, as a result of which the Company's business will be in the field of renewable fuels rather than biotechnology and medical devices.

Shareholders of record of the Company as of the close of business in New York on August 21, 2007, are entitled to vote at the Meeting.

The Notice and Proxy Statement associated with the Meeting is available at http://www.sec.gov, the website of the U.S. Securities and Exchange Commission. Proxy materials will be sent to all shareholders of record.

Shareholders who need additional copies of the proxy materials or have questions regarding the Meeting, including the procedures for voting shares, should call The Altman Group, the Company's proxy solicitor, toll-free at 1-800-622-1588 (from the United States) or 1-201-806-7300 (from other locations).

Closing of the transactions contemplated by the Agreement is subject to the completion of due diligence by the parties, the receipt of the necessary corporate, regulatory and third party approvals, including Healthcare's shareholders and the approval of the Israeli District Court and other closing conditions. No assurance can be given that the transactions contemplated by the Agreement will close.

About Healthcare Technologies

Healthcare Technologies Ltd. through it subsidiaries and affiliates Gamidor Diagnostics (1984) Ltd., Danyel Biotech Ltd. and Savyon Diagnostics Ltd., specializes in the development, manufacturing and marketing of clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point of care sites worldwide.

About NexGen Biofuels, Inc.

NexGen is operating in the business of alternative fuels. NexGen plans to build and operate four ethanol and one biodiesel plant with production primarily within in the United States. NexGen is currently in the process of acquiring and developing its proposed plants and has not conducted any significant business operations or generated any operating revenues to date. It is NexGen's intention to produce 100 million gallons of annual ethanol production per ethanol site, and 100 million gallons of annual biodiesel production.

SAFE HARBOR: This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of Healthcare Technologies Ltd. Many factors could cause the actual results, performance or achievements of Healthcare or the above described transaction to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others: satisfaction of the closing conditions to the agreement; receipt of shareholder, regulatory and third party approvals, including the approval of the District Court of Tel Aviv; the satisfaction and completion of due diligence by the parties to the agreement; the receipt by Healthcare of a satisfactory valuation of NexGen's assets; a non-binding offer to purchase Healthcare's subsidiaries previously sent to us by Inverness Medical Innovations Inc., to which, as any negotiations with Inverness would be a breach of the NexGen Agreement, Healthcare has refrained from any discussions with Inverness. Readers are referred to the documents filed by the company with the Securities and Exchange Commission, specifically the Proxy Statement concerning the meeting and most recent report on Form 20F that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

For: Healthcare Technologies, Ltd.

CONTACT: Eran Rotem, CFO

+972-3-9277232/3


'/>"/>
SOURCE Healthcare Technologies Ltd

Copyright©2007 PR Newswire.

Related biology technology :

1. Web-based reporting credited with states top healthcare ranking
2. Visions: Preizler offers insurers perspective on healthcare IT
3. Federal bill would set healthcare IT standards
4. IRS ruling could speed healthcare technology adoption
5. Bill would provide federal aid for healthcare IT
6. DHC 2007: Hayden says technology creates magic moment for healthcare delivery
7. Digital Healthcare Conference 2007: Mounting obstacles for health IT
8. Georgia healthcare system to install GEs radio frequency ID
9. GE Healthcare leads compact ultrasound market
10. CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare
11. Merge Healthcare suffers $258M loss in `06
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical ... for a host of launch activities including the identification ... this launch activity is especially high in the oncology ... Best Practices and the Role of Medical Affairs ... companies focused on oncology therapies find better ways to ...
(Date:2/5/2016)... 2016 Amarantus BioScience Holdings, Inc. ... on developing products for Regenerative Medicine, Neurology and Orphan ... Designation (RPDD) from the US Food and Drug Administration ... was previously granted orphan drug designation (ODD) by the ... BioScience Holdings, Inc. (OTCQB: AMBS), a ...
(Date:2/4/2016)... ... 04, 2016 , ... Morf Media Inc ., shaping ... FDA compliance training course, Writing Effective SOPs (Standard Operating ... course on Morf Playbook—now conveniently available on smartphones and PCs--provides step by step ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Sangamo BioSciences, ... genome editing, announced today that Edward Lanphier , ... update on the progress of Sangamo,s ZFP Therapeutic ® ... business strategy at 2:40 pm ET on Thursday, February ... Annual Global Healthcare Conference. The conference is being held ...
Breaking Biology Technology:
(Date:2/1/2016)... smart wallet ( www.wocketwallet.com ) announces the launch of a new video ... Las Vegas , where Joey appeared at the Wocket ... Vegas , where Joey appeared at the Wocket booth to meet ... filmed at the Consumer Electronics Show (CES2016) in Las Vegas ... greet fans. --> --> The ...
(Date:1/25/2016)... 2016  Glencoe Software, the world-leading supplier of image ... will provide the data management solution OMERO Plus for ... Photo - ... Phenotypic analysis measures the characteristics and behavior ... between states such as health and disease, the presence ...
(Date:1/20/2016)... A market that just keeps on growing. ... explosion in genomics knowledge. Learn all about it in ... of dynamic trends are pushing market growth and company ... pharmacogenomics - pathogen evolution - next generation sequencing - ... understanding of the role of genetic material in Disease ...
Breaking Biology News(10 mins):